Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.

Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT. Clin Adv Hematol Oncol. 2016 May;14 Suppl 7(5):13-15 Authors: PMID: 27168107 [PubMed - as supplied by publisher]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research